Establishing a whole blood CD4⁺ T cell immunity measurement to predict response to anti-PD-1.

ABSTRACT:

Background

Biomarkers that can accurately predict the efficacy of immune checkpoint inhibitors (ICIs) against programmed death 1 (PD-1) ligand in cancer immunotherapy are urgently needed. We have previously reported a novel formula that predicts the response to treatment with second-line nivolumab with high sensitivity and specificity in patients with non-small cell lung cancer (NSCLC) previously treated with chemotherapy. The formula was based on the percentages of CD62L^lowCD4⁺ T cells (effector T cells; %Teff) and CD4⁺CD25⁺FOXP3⁺ T cells (regulatory T cells; %Treg) in the peripheral blood before treatment estimated using the peripheral blood mononuclear cell (PBMC) method. Here, we investigated the applicability of the formul

SUBMITTER: Yamaguchi O 

PROVIDER: S-EPMC9759885 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature